Table 1 Studies Comparing Outcomes in Advanced Malignancy Patients on Treatment with Anti-Programmed Cell Death Protein 1 (PD-1) and Anti-Programmed Death-Ligand 1 (PD-L1) Antibodies
From: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
Study | Disease | Number of Patients | Checkpoint Inhibitor(s) Used | Survival Endpoints Between Patients With and Without IRAES | Response Endpoints Between Patients With and Without IRAEs |
|---|---|---|---|---|---|
Grangeon et al. [18] | NSCLC | 270 | Anti-PD-1 and anti-PD-L1 | OS (HR 0.29; 95% CI 0.18–0.46; p = .001), PFS (HR 0.42; 95% CI 0.32–0.57; p < .001) | ORR (22.9% vs 5.7%, p < .0001), DCR (76% vs 58%, p < .001) |
Ricciuti et al. [34] | NSCLC | 195 | Nivolumab | OS (HR 0.33; 95% CI 0.23–0.47; p < .001), PFS (HR 0.41; 95% CI 0.3–0.57; p < .001) | ORR (43.5% vs 10%, p < .001), DCR (70.5% vs 18.1%, p < .0001) |
Riudavets et al. [13] | NSCLC, UCC and melanoma | 178 | Nivolumab, pembrolizumab and atezolizumab | OS (37.3 vs 7.8 months, p < 0.0001), PFS (7.9 vs 2.6 months, p < 0.0001) | Not provided |
Sato et al.a [19] | NSCLC | 38 | Nivolumab | PFS (HR 0.1; 95% CI .02–.37; p < .001) | ORR (63.6% vs 7.4%, p < .01) |
Weber et al. [38] | Melanoma | 576 | Nivolumab | PFS (no significant differences between either group; HR or p value not provided) | ORR (48.6% vs 17.8%, p < .001) |
Indini et al. [37] | Melanoma | 173 | Anti-PD-1 | OS (HR 0.39; 95% CI 0.18–0.81; p = .007), PFS (HR 0.47; 95% CI 0.26–0.86; p = .016) | ORR (HR 1.95; 95% CI 0.91–4.15; p < 0.082), DCR (HR 1.98; 95% CI 1.07–3.67; p < 0.029) |
Elias et al. [17] | RCC | 90 | Anti-PD-1 | OS (HR 0.38; 95% CI 0.18–0.79; p = .01) and TTNT (HR 0.48; 95% CI 0.28–0.83; p = .008) | Not provided |
Verzoni et al. [39] | RCC | 389 | Nivolumab | OS (HR .57; 95% CI .35–.93; p = .02) | Not provided |
Maher et al. [20] | UCC | 1747 | Atezolizumab or pembrolizumab | OS (HR 0.53; 95% CI 0.43–0.66) | Not provided |
Morales-Berera et al. [40] | UCC | 52 | Anti-PD-1 or anti-PD-L1 | OS (21.91 vs 6.47 months, p = .004) | DCR (79% vs 36.3%, p = .002) |
Das et al. [41] | GI | 61 | Anti-PD-1 monotherapy or in combination | OS (32.4 vs 8.5 months, p = .0036), PFS (32.4 vs 4.8 months, p = .0001) | Not provided |
Masuda et al. [42] | Gastric | 65 | Nivolumab | OS (HR .17, p < .001), PFS (HR .11, p < .001) | Not provided |
Foster et al. [43] | HNSCC | 114 | Anti PD-1 | OS (12.5 vs 6.8 months, p = .0007), PFS (6.9 vs 2.1 months, p = .0004) | ORR (30.6% vs 12.3%, p = .02) |